To The Moon
Home
News
TigerAI
Log In
Sign Up
Roy yang
+Follow
Posts · 0
Posts · 0
Following · 0
Following · 0
Followers · 0
Followers · 0
Roy yang
Roy yang
·
2022-06-27
$Nasdaq100 Bear 3X ETF(SQQQ)$
Sweet
看
2.47K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-06-09
$Futu Holdings Limited(FUTU)$
Bear [Put] [Weak]
看
3.56K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-06-07
This week up
@山中老虎：
$Futu Holdings Limited(FUTU)$will up more or down?[smile]
$Futu Holdings Limited(FUTU)$will up more or down?[smile]
看
2.64K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-06-06
$Futu Holdings Limited(FUTU)$
Bull trap
看
3.66K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-05-30
Pump and dump
@gsazer：
$DYNA-MAC HOLDINGS LTD.(NO4.SI)$woke up after long slumber
$DYNA-MAC HOLDINGS LTD.(NO4.SI)$woke up after long slumber
看
2.76K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-05-07
Whoa
Sorry, this post has been deleted
看
2.37K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-03-15
$Futu Holdings Limited(FUTU)$
gged
看
2.35K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-03-15
Sian.. .
看
2.37K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Roy yang
Roy yang
·
2022-02-02
Good
AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi
AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster an
AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi
看
2.26K
回复
Comment
点赞
3
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4097238453090300","uuid":"4097238453090300","gmtCreate":1635489159285,"gmtModify":1635779542851,"name":"Roy yang","pinyin":"royyangroyyang","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":72,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.26","exceedPercentage":"93.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9046605133,"gmtCreate":1656337003322,"gmtModify":1676535808452,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SQQQ\">$Nasdaq100 Bear 3X ETF(SQQQ)$</a>Sweet","listText":"<a href=\"https://ttm.financial/S/SQQQ\">$Nasdaq100 Bear 3X ETF(SQQQ)$</a>Sweet","text":"$Nasdaq100 Bear 3X ETF(SQQQ)$Sweet","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046605133","isVote":1,"tweetType":1,"viewCount":2467,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9058315647,"gmtCreate":1654786256189,"gmtModify":1676535510824,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Bear [Put] [Weak] ","listText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Bear [Put] [Weak] ","text":"$Futu Holdings Limited(FUTU)$Bear [Put] [Weak]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9058315647","isVote":1,"tweetType":1,"viewCount":3555,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9053297802,"gmtCreate":1654555177906,"gmtModify":1676535465407,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"This week up","listText":"This week up","text":"This week up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9053297802","repostId":"9053677319","repostType":1,"repost":{"id":9053677319,"gmtCreate":1654553062231,"gmtModify":1676535464892,"author":{"id":"4108022953050440","authorId":"4108022953050440","name":"山中老虎","avatar":"https://community-static.tradeup.com/news/5aad0c9c6ba0711a65676e88e60cba35","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4108022953050440","idStr":"4108022953050440"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>will up more or down?[smile] ","listText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>will up more or down?[smile] ","text":"$Futu Holdings Limited(FUTU)$will up more or down?[smile]","images":[{"img":"https://community-static.tradeup.com/news/a57964339f2fcdef12836858a0bd3e8c","width":"1080","height":"2530"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9053677319","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2641,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9053634893,"gmtCreate":1654526869012,"gmtModify":1676535463027,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Bull trap","listText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>Bull trap","text":"$Futu Holdings Limited(FUTU)$Bull trap","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9053634893","isVote":1,"tweetType":1,"viewCount":3662,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"content":"take profit, this is high jump now is bear market ,danger if fed add interest this Friday will drop back to 36+ now buy will stuck..too high","text":"take profit, this is high jump now is bear market ,danger if fed add interest this Friday will drop back to 36+ now buy will stuck..too high","html":"take profit, this is high jump now is bear market ,danger if fed add interest this Friday will drop back to 36+ now buy will stuck..too high"},{"author":{"id":"3576759208994289","authorId":"3576759208994289","name":"CashCity","avatar":"https://static.tigerbbs.com/c5cf91d5f3d2d348fadcd1f4cd2a3fc7","crmLevel":12,"crmLevelSwitch":1,"authorIdStr":"3576759208994289","idStr":"3576759208994289"},"content":"Up 20% on earnings = bulltrap?[Cover your face][Laughs and cries]","text":"Up 20% on earnings = bulltrap?[Cover your face][Laughs and cries]","html":"Up 20% on earnings = bulltrap?[Cover your face][Laughs and cries]"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9024495718,"gmtCreate":1653900526734,"gmtModify":1676535360142,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"Pump and dump","listText":"Pump and dump","text":"Pump and dump","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024495718","repostId":"9024208996","repostType":1,"repost":{"id":9024208996,"gmtCreate":1653871099415,"gmtModify":1676535354004,"author":{"id":"4109224528330880","authorId":"4109224528330880","name":"gsazer","avatar":"https://community-static.tradeup.com/news/ccc49b4014f8640635428896f537dd50","crmLevel":12,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4109224528330880","idStr":"4109224528330880"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NO4.SI\">$DYNA-MAC HOLDINGS LTD.(NO4.SI)$</a>woke up after long slumber","listText":"<a href=\"https://ttm.financial/S/NO4.SI\">$DYNA-MAC HOLDINGS LTD.(NO4.SI)$</a>woke up after long slumber","text":"$DYNA-MAC HOLDINGS LTD.(NO4.SI)$woke up after long slumber","images":[{"img":"https://community-static.tradeup.com/news/0d9b48b0695e60605220160801bb4ffa","width":"1080","height":"3326"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9024208996","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2764,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9066152737,"gmtCreate":1651880873329,"gmtModify":1676534988135,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"Whoa","listText":"Whoa","text":"Whoa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066152737","repostId":"2233939112","repostType":2,"isVote":1,"tweetType":1,"viewCount":2370,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9032853151,"gmtCreate":1647335619259,"gmtModify":1676534217879,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>gged","listText":"<a href=\"https://ttm.financial/S/FUTU\">$Futu Holdings Limited(FUTU)$</a>gged","text":"$Futu Holdings Limited(FUTU)$gged","images":[{"img":"https://community-static.tradeup.com/news/44585801ff45fbccd87f517a02c7e877","width":"840","height":"1161"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032853151","isVote":1,"tweetType":1,"viewCount":2345,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9032850914,"gmtCreate":1647334972827,"gmtModify":1676534217817,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"Sian.. .","listText":"Sian.. .","text":"Sian.. .","images":[{"img":"https://community-static.tradeup.com/news/44585801ff45fbccd87f517a02c7e877","width":"840","height":"1161"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9032850914","isVote":1,"tweetType":1,"viewCount":2365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9091168289,"gmtCreate":1643807713364,"gmtModify":1676533858281,"author":{"id":"4097238453090300","authorId":"4097238453090300","name":"Roy yang","avatar":"https://static.tigerbbs.com/6cb899e53e5a67fe8973ebb5613f8c79","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4097238453090300","idStr":"4097238453090300"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091168289","repostId":"2208368622","repostType":4,"repost":{"id":"2208368622","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1643805900,"share":"https://ttm.financial/m/news/2208368622?lang=en_US&edition=fundamental","pubTime":"2022-02-02 20:45","market":"us","language":"en","title":"AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi","url":"https://stock-news.laohu8.com/highlight/detail?id=2208368622","media":"Dow Jones","summary":"AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster an","content":"<html><head></head><body><p>AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.</p><p>The company's best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.</p><p>Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.</p><p>Total revenue of $14.89 billion also missed estimates of $14.97 billion.</p><p>However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.</p><p>Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.</p><p>Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.</p><p>Excluding items, AbbVie earned $3.31 per share.</p><p>The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-02-02 20:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.</p><p>The company's best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.</p><p>Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.</p><p>Total revenue of $14.89 billion also missed estimates of $14.97 billion.</p><p>However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.</p><p>Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.</p><p>Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.</p><p>Excluding items, AbbVie earned $3.31 per share.</p><p>The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4534":"瑞士信贷持仓","BK4139":"生物科技","ABBV":"艾伯维公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4559":"巴菲特持仓","BK4566":"资本集团","BK4550":"红杉资本持仓"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2208368622","content_text":"AbbVie Inc forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.The company's best-selling drug Humira is expected to face competition from rivals in the United States in 2023 after it loses exclusivity, and the drugmaker is counting on Botox as well as newer drugs, Skyrizi and Rinvoq, to soften the expected blow to sales.Sales of Humira, which is already facing copycat rivals in Europe, rose 3.5% to $5.33 billion in the fourth quarter, missing estimates of $5.41 billion, according to Refinitiv IBES data.Total revenue of $14.89 billion also missed estimates of $14.97 billion.However, the company reported sales of $895 million for Skyrizi, which beat estimates of $867.22 million, and $626 million in Botox sales for cosmetic uses, which topped estimates of $569.78 million.Sales of Rinvoq, which belongs to a class of drugs known JAK inhibitors, jumped 84.4% to $517 million.Net earnings rose to $4.04 billion, or $2.26 per share, in the quarter ended Dec. 31, from $36 million, or $0.01 per share, a year ago. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year.Excluding items, AbbVie earned $3.31 per share.The company said it expects 2022 adjusted profit to be between $14.00 and $14.20 per share. Analysts were expecting a profit of $13.99 per share.","news_type":1,"symbols_score_info":{"ABBV":1}},"isVote":1,"tweetType":1,"viewCount":2259,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}